Search results for "molecular targeted therapy"

showing 10 items of 163 documents

Bioactive pyrrole-based compounds with target selectivity

2020

The discovery of novel synthetic compounds with drug-like properties is an ongoing challenge in medicinal chemistry. Natural products have inspired the synthesis of compounds for pharmaceutical application, most of which are based on N-heterocyclic motifs. Among these, the pyrrole ring is one of the most explored heterocycles in drug discovery programs for several therapeutic areas, confirmed by the high number of pyrrole-based drugs reaching the market. In the present review, we focused on pyrrole and its hetero-fused derivatives with anticancer, antimicrobial, and antiviral activities, reported in the literature between 2015 and 2019, for which a specific target was identified, being resp…

Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antineoplastic AgentsReview ArticlePyrroleAntiviral Agentschemistry.chemical_compoundAnti-Infective AgentsDrug DiscoveryHumansPyrrolesMolecular Targeted TherapyAntiviralTargeted compoundsPyrrolePharmacologyDrug discoveryChemistryOrganic ChemistryCOVID-19Biological activityGeneral MedicineAntimicrobialSettore CHIM/08 - Chimica FarmaceuticaCombinatorial chemistryAnticancerDrug DesignAntimicrobialPharmacophoreSelectivityEuropean Journal of Medicinal Chemistry
researchProduct

Advances in Targeting Signal Transduction Pathways

2012

// James A. McCubrey 1 , Linda S. Steelman 1 , William H. Chappell 1 , Lin Sun 1,2 , Nicole M. Davis 1 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Lucio Cocco 3 , Camilla Evangelisti 4 , Francesca Chiarini 4 , Alberto M. Martelli 3,4 , Massimo Libra 5 , Saverio Candido 5 , Giovanni Ligresti 5 , Grazia Malaponte 5 , Maria C. Mazzarino 5 , Paolo Fagone 5 , Marco Donia 5 , Ferdinando Nicoletti 5 , Jerry Polesel 6 , Renato Talamini 6 , Jorg Basecke 7 , Sanja Mijatovic 8 , Danijela Maksimovic-Ivanic 8 , Michele Milella 9 , Agostino Tafuri 10 , Joanna Dulinska-Litewka 11 , Piotr Laidler 11 , Antonio B. D’Assoro 12 , Lyudmyla Drobot 13 , Kazuo Umezawa 14 , Giuseppe Montalto 15 , Melchiorre Cer…

cancer stem cellsAMPKtherapy resistanceReviewsLibrary scienceAntineoplastic AgentsrafBiologyPI3Kampk03 medical and health sciences0302 clinical medicineCANCER STEM CELLSNeoplasmsAnimalsHumansUniversity medicalMolecular Targeted TherapyAkt; AMPK; Cancer stem cells; Metformin; MTOR; PI3K; Raf; Targeted therapy; Therapy resistanceTreatment resistanceProtein Kinase Inhibitors030304 developmental biology0303 health sciencesRoswell Park Cancer InstituteAktCancer stem cellAKTMTORAMP-ACTIVATED PROTEIN KINASE (AMPK)Raftargeted therapyMetformin3. Good healthGene Expression Regulation NeoplasticCell stressOncologyDrug Resistance NeoplasmDrug Designtargeted therapy; metformin; therapy resistance; pi3k; akt; ampk; cancer stem cells; raf; mtor030220 oncology & carcinogenesisMutationmTORMolecular targetsCancer researchmetforminSignal Transduction
researchProduct

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

2017

Abstract: Introduction: The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR. Areas Covered: This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies. Expert opinion: Most of the TKR share …

0301 basic medicineFibroblast Growth FactorDruggabilityFibroblast growth factorTyrosine-kinase inhibitorReceptor tyrosine kinase0302 clinical medicineNeoplasmsFGFR inhibitorsFGFMolecular Targeted TherapyCancerCancer; FGF; FGFR; FGFR inhibitors; Drug Resistance Neoplasm; Fibroblast Growth Factors; Gene Fusion; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Receptors Fibroblast Growth Factor; Signal Transduction; Hematology; Oncology; Geriatrics and GerontologybiologyFGFRHematologyFGFR inhibitorOncologyFibroblast growth factor receptor030220 oncology & carcinogenesisembryonic structuresSignal transductionbiological phenomena cell phenomena and immunityGene FusionHumanSignal Transductionmusculoskeletal diseasesanimal structuresmedicine.drug_classProtein Kinase Inhibitor03 medical and health sciencesmedicineHumansProtein Kinase InhibitorsCancer; FGF; FGFR; FGFR inhibitorsbusiness.industryCancermedicine.diseaseMolecular biologyReceptors Fibroblast Growth FactorFibroblast Growth Factors030104 developmental biologyDrug Resistance NeoplasmCancer cellMutationbiology.proteinNeoplasmHuman medicineGeriatrics and GerontologybusinessCritical reviews in oncology/hematology
researchProduct

Current questions for the treatment of advanced gastric cancer.

2013

Abstract Background Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in advanced gastric cancer. Material and methods Seven questions of special clinical interest have been formulated previously to the literature review. With the aim of answering each of these questions, a specific search of the relevant trials and meta-analyses published or communicated from 1990 to date was performed. Results Patients treated with CT have a survival benef…

Oncologymedicine.medical_specialtymedicine.medical_treatmentAntibodies Monoclonal HumanizedTargeted therapyTrastuzumabStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingMolecular Targeted TherapyRandomized Controlled Trials as TopicPerformance statusbusiness.industryCancerGeneral MedicineTrastuzumabmedicine.diseaseSurgeryOxaliplatinIrinotecanRegimenOncologyDocetaxelbusinessmedicine.drugCancer treatment reviews
researchProduct

Therapeutic targets for overactive bladder other than smooth muscle

2015

For a long time, our concepts of regulation of urinary bladder function in health and disease as well as of the target structures of therapeutics have focused on detrusor smooth muscle cells. However, other structures including urothelium, afferent nerves and bladder blood vessels may also be important in pathophysiology and its treatment.Based on a selective review of literature, we discuss the role of urothelium, afferent nerve fibers and bladder blood vessels in bladder pathophysiology and as targets for treatment.There is solid evidence now that multiple anatomical structures within the urinary bladder contribute to the regulation of its function and hence may be targets for established…

Pathologymedicine.medical_specialtyMyocytes Smooth MuscleUrinary BladderClinical BiochemistryAnatomical structuresDiseaseurologic and male genital diseasesNerve FibersSmooth muscleAfferentDrug DiscoverymedicineAnimalsHumansMolecular Targeted TherapyUrotheliumPharmacologyAfferent PathwaysUrinary bladderUrinary Bladder Overactivebusiness.industrymedicine.diseasefemale genital diseases and pregnancy complicationsPathophysiologymedicine.anatomical_structureOveractive bladderDrug DesignMolecular MedicineUrotheliumbusinessNeuroscienceExpert Opinion on Therapeutic Targets
researchProduct

The emerging role of miRNA-132/212 cluster in neurologic and cardiovascular diseases: Neuroprotective role in cells with prolonged longevity

2021

Abstract miRNA-132/212 are small regulators of gene expression with a function that fulfills a vital function in diverse biological processes including neuroprotection of cells with prolonged longevity in neurons and the cardiovascular system. In neurons, miRNA-132 appears to be essential for controlling differentiation, development, and neural functioning. Indeed, it also universally promotes axon evolution, nervous migration, plasticity as well, it is suggested to be neuroprotective against neurodegenerative diseases. Moreover, miRNA-132/212 disorder leads to neural developmental perturbation, and the development of degenerative disorders covering Alzheimer’s, Parkinson’s, and epilepsy’s …

Agingmedicine.medical_specialtyNeurologyDegenerative Disordermedia_common.quotation_subjectNeuroprotection03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmicroRNAAnimalsHumansMedicineMyocytes CardiacMolecular Targeted TherapyAxonCellular SenescenceComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonNeurons0303 health sciencesbusiness.industryNeurodegenerationAutophagyLongevityNeurodegenerative Diseasesmedicine.diseaseNeuroprotection3. Good healthMicroRNAsmedicine.anatomical_structureGene Expression RegulationCardiovascular DiseasesbusinessNeuroscience030217 neurology & neurosurgeryDevelopmental Biology
researchProduct

Presenilin is the molecular target of acidic γ-secretase modulators in living cells.

2012

The intramembrane-cleaving protease γ-secretase catalyzes the last step in the generation of toxic amyloid-β (Aβ) peptides and is a principal therapeutic target in Alzheimer's disease. Both preclinical and clinical studies have demonstrated that inhibition of γ-secretase is associated with prohibitive side effects due to suppression of Notch processing and signaling. Potentially safer are γ-secretase modulators (GSMs), which are small molecules that selectively lower generation of the highly amyloidogenic Aβ42 peptides but spare Notch processing. GSMs with nanomolar potency and favorable pharmacological properties have been described, but the molecular mechanism of GSMs remains uncertain an…

CellsProtein subunitDrug Evaluation PreclinicalNotch signaling pathwaylcsh:MedicineCHO CellsBiochemistryModels BiologicalPresenilinInhibitory Concentration 50CricetulusCricetinaeAmyloid precursor proteinAnimalsHumansMolecular Targeted TherapyEnzyme InhibitorsMode of actionlcsh:ScienceBiologyCells CulturedMultidisciplinarybiologyEnzyme ClassesChemistryAnti-Inflammatory Agents Non-SteroidalHEK 293 cellslcsh:RChemical ReactionsPresenilinsProteinsSmall moleculeEnzymesChemistryHEK293 CellsNeurologyBiochemistrybiology.proteinMedicineDementialcsh:QAmyloid Precursor Protein SecretasesAmyloid precursor protein secretaseResearch ArticlePLoS ONE
researchProduct

Targeted therapy of liver fibrosis/cirrhosis and its complications.

2011

Department of Pharmacokinetics, Toxicology, and Targeting, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands; Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA; Division of Molecular and Translational Medicine, Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany

Liver Cirrhosismedicine.medical_specialtyCirrhosisMacrophageKupffer CellsLiver fibrosismedicine.medical_treatmentKupffer cellTargeted therapyMyoblastsDrug Delivery SystemsInternal medicinemedicineHepatic Stellate CellsHumansHepatocyteMolecular Targeted TherapyHCCMyofibroblastTargetingDrug CarriersHepatologybusiness.industryGeneral surgeryAntifibrotic therapyMedical schoolTranslational medicineHepatologyFibroblastsmedicine.diseaseFibrosisLiverStellate cellHepatocytesDrugbusinessCholangiocyteJournal of hepatology
researchProduct

Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis

2017

medicine.medical_specialtyImmunologyDisease03 medical and health sciencesPsoriatic arthritis0302 clinical medicineHumansImmunology and AllergyMedicineSpondylitis AnkylosingMolecular Targeted TherapyProtein Kinase Inhibitors030203 arthritis & rheumatologyClinical Trials as TopicTofacitinibbusiness.industrymedicine.diseaseDermatologyOncologyNilotinibAntirheumatic Agents030220 oncology & carcinogenesisApremilastbusinessAntirheumatic drugsmedicine.drugImmunotherapy
researchProduct

In silico identification of small molecules as new cdc25 inhibitors through the correlation between chemosensitivity and protein expression pattern

2021

The cell division cycle 25 (Cdc25) protein family plays a crucial role in controlling cell proliferation, making it an excellent target for cancer therapy. In this work, a set of small molecules were identified as Cdc25 modulators by applying a mixed ligand-structure-based approach and taking advantage of the correlation between the chemosensitivity of selected structures and the protein expression pattern of the proposed target. In the first step of the in silico protocol, a set of molecules acting as Cdc25 inhibitors were identified through a new ligand-based protocol and the evaluation of a large database of molecular structures. Subsequently, induced-fit docking (IFD) studies allowed us…

0301 basic medicineHepG2Protein familyCdc25In silicoAntiproliferative activityCell cycleLigandsCatalysisArticleInorganic Chemistrylcsh:Chemistry03 medical and health sciencesCdc250302 clinical medicineCDC2 Protein KinaseDrug DiscoveryHumanscdc25 PhosphatasesComputer SimulationMolecular Targeted TherapyPhysical and Theoretical ChemistryPhosphorylationMolecular Biologylcsh:QH301-705.5DRUDITSpectroscopyBinding SitesbiologyCell growthChemistryOrganic ChemistryGeneral MedicineHep G2 CellsCell cycleAntiproliferative activity; Cdc25; Cell cycle; DRUDIT; HepG2; Molecular dockingLigand (biochemistry)Small moleculeComputer Science Applications030104 developmental biologyBiochemistrylcsh:Biology (General)lcsh:QD1-999Docking (molecular)030220 oncology & carcinogenesisMolecular dockingbiology.proteinDrug Screening Assays Antitumor
researchProduct